Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 3, 2011, Pages 384-394

  Karpel Massler, Georg ^a   Wirtz, Christian R ^a   Halatsch, Marc Eric ^a  

^a UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

Erlotinib; High grade glioma; Kit; Pralatrexate; Romidepsin; Vascular disrupting agents

Indexed keywords

4 PHENYLBUTYRIC ACID; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; HISTONE DEACETYLASE; HYDROXYUREA; IMATINIB; IRINOTECAN; METHOTREXATE; N (4 TRIFLUOROMETHOXYPHENYL) 3 [(QUINOLIN 4 YLMETHYL)AMINO]THIOPHENE 2 CARBOXAMIDE; OSI 930; PACLITAXEL; PRALATREXATE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; ROMIDEPSIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; TEMOZOLOMIDE; THALIDOMIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PAIN; CANCER RADIOTHERAPY; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FATIGUE; GLIOBLASTOMA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROSURGERY; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; TUMOR VOLUME; UTERINE TUBE CARCINOMA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DRUG COMBINATIONS; DRUG SYNERGISM; GLIOMA; HUMANS; MODELS, BIOLOGICAL; NEOPLASM GRADING; QUINAZOLINES;

EID: 80052341035     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211796957748     Document Type: Review

References (102)

1. Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoom M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Libermann T, Nusbaum H, Razon N, Kris R, Lax I, Soreq H, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985; 313: 144-147.
3. Ekstrand A, James C, Cavanee W, Seliger B, Pettersson R, Collins V. Genes for epidermal growth factor receptor, transforming growth factor alpha and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991; 51: 2164-2172.
4. Karpel-Massler G, Schmidt U, Unterberg A, Halatsch M. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas - where do we stand? Mol Cancer Res 2009; 7: 1000-1012.
5. Scagliotti G, Selvaggi G, Novello S, Hirsch F. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10: 4227s-4232s.
6. Busse D, Doughty R, Ramsey T, Russell W, Price J, Flanagan W, et al. Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1 independent of MAPK activity. J Biol Chem 2000; 275: 6987-6995.
7. Arteaga C. The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19: 32S-40S.
8. Chu C, Everiss K, Wikstrand C, Batra S, Kung H, Bigner D. Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 1997; 324: 855-861.
9. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
10. Paez J, Jänne P, Lee J, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
11. Lal A, Glazer C, Martinson H, Friedman H, Archer G, Sampson J, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002; 62: 3335-3339.
12. Halatsch M-E, Gehrke E, Vougioukas V, Bötefür I, Efferth T, Gebhardt E, et al. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorageindependent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J Neurosurg 2004; 100: 523-533.
13. Raizer J, Abrey L, Lassman A, Chang S, Lamborn K, Kuhn J, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neurooncol 2010; 12: 95-103.
14. van den Bent M, Brandes A, Rampling R, Kouwenhoven M, Kros J, Carpentier A, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009; 27: 1268-1274.
15. Brown P, Krishnan S, Sarkaria J, Wu W, Jaeckle K, Uhm J, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008; 26: 5603-5609.
16. Prados M, Chang S, Butowski N, DeBoer R, Parvataneni R, Carliner H, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009; 27: 579-584.
17. Peereboom D, Shepard D, Ahluwalia M, Brewer C, Agarwal N, Stevens G, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2010; 98: 93-99.
18. Wang M, Lu K, Zhu S, Dia E, Vivanco I, Shackleford G, et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTENdeficient and PTEN-intact glioblastoma cells. Cancer Res 2006; 66: 7864-7869.
19. Fan Q-W, Cheng C, Nicolaides T, Hackett C, Knight Z, Shokat K, et al. A dual phosphoinositide-3-kinase anti/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007; 67: 7960-7965.
20. Doherty L, Gigas D, Kesari S, Drappatz J, Kim R, Zimmermann J, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006; 67: 156-158.
21. Reardon D, Desjardins A, Vredenburgh J, Gururangan S, Friedman A, Herndon II J, et al. Phase II trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 2010; 96: 219-230.
22. Sathornsumetee S, Desjardins A, Vredenburgh J, McLendon R, Marcello J, Herndon II J, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neurooncol 2010; 12: 1300-1310.
23. Krishnan S, Brown P, Ballmann K, Fiveash J, Uhm J, Giannini C, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 2006; 65: 1192-1199.
24. Prados M, Lamborn K, Chang S, Burton E, Butowski N, Malec M, et al. Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neurooncol 2006; 8: 67-78.
25. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-5468.
26. Marsoni S, Damia G, Camboni G. A work in progress: The clinical development of histone deacetylase inhibitors. Epigenetics 2008; 3: 164-171.
27. Svechnikova I, Almqvist PM, Ekstrom TJ. HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. Int J Oncol 2008; 32: 821-827.
28. Yoo CB, Jones PA. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
29. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 769-774.
30. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76.
31. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77-84.
32. Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHAinduced apoptosis. Cell Death Differ 2006; 13: 129-140.
33. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005; 102: 16090-16095.
34. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
35. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates Hsp90 acetylation and chaperonedependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-607.
36. Whitesell L, Lindquist SL. Hsp90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-772.
37. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014-10019.
38. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000; 83: 817-825.
39. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994; 47: 301-310.
40. Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: A case series report. Haematologica 2009; 94: 1618-1622.
41. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009; 15: 3958-3969.
42. Byrd J, Marcucci G, Parthun M, Xiao J, Klisovic R, Moran M, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-967.
43. Odenike O, Alkan S, Sher D, Godwin J, Huo D, Brandt S, et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 2008; 14: 7095-7101.
44. Piekarz R, Frye R, Turner M, Wright J, Allen S, Kirschbaum M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous Tcell lymphoma. J Clin Oncol 2009; 27: 5410-5417.
45. Whittaker S, Demierre M-F, Kim E, Rook A, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-4491.
46. Camphausen K, Cerna D, Scott T, Sproull M, Burgan W, Cerra M, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005; 114: 380-386.
47. Entin-Meer M, Yang X, Van den Berg S, Lamborn K, Nudelman A, Rephaeli A, et al. In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neurooncol 2007; 9: 82-88.
48. Lucio-Eterovic AK, Cortez MA, Valera ET, Motta FJ, Queiroz RG, Machado HR, et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: Class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008; 8: 243.
49. Sawa H, Murakami H, Kumagai M, Nakasato M, Yamauchi S, Matsuyama N, et al. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol 2004; 107: 523-531.
50. Frenkel, E. Combination therapy for cancer. WO2008127659 (2008).
51. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-703.
52. Yarden Y, Kuang W-J, Yang-Feng T, Coussens L, Munemitsu S, Dull T, et al. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 11: 3341-3351.
53. Nocka K, Buck J, Levi E, Besmer P. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J 1990; 9: 3287-3294.
54. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004; 23: 3999-4006.
55. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC, et al. Structure of a c-kit product complex reveals the basis for kinase transactivation. J Biol Chem 2003; 278: 31461-31464.
56. Ishikawa K, Komuro T, Hirota S, Kitamura Y. Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: A comparison of control and Ws/Ws mutant rats. Cell Tissue Res 1997; 289: 137-143.
57. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992; 52: 6139-6143.
58. Nocka K, Majumder S, Chabot B, Ray P, Cervone M, Bernstein A, et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - evidence for an impaired c-kit kinase in mutant mice. Genes Dev 1989; 3: 816-826.
59. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992; 80: 374-381.
60. Duensing S, Duensing A. Targeted therapies of gastrointestinal stromal tumors (GIST) - the next frontiers. Biochem Pharmacol 2010; 80: 575-583.
61. Woodman SE, Davies MA. Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 2010; 80: 568-574.
62. Cetin N, Dienel G, Gokden M. CD117 expression in glial tumors. J Neurooncol 2005; 75: 195-202.
63. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 2005; 207: 224-231.
64. Puputti M, Tynninen O, Sihto H, Blom T, Maenpaa H, Isola J, et al. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res 2006; 4: 927-934.
65. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625.
66. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632.
67. Gold JS, van der Zwan SM, Gonen M, Maki RG, Singer S, Brennan MF, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007; 14: 134-142.
68. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134.
69. Hagerstrand D, Hesselager G, Achterberg S. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 2006; 25: 4913-4922.
70. Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, Bischof M, et al. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec®). Strahlenther Onkol 2006; 7: 400-407.
71. Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, et al. Phase II study of neoadjuvant imatinib in glioblastoma: Evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 2009; 15: 6258-6266.
72. Wen P, Yung W, Lamborn K, Dahia P, Wang Y, Peng B, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American BrainTumor Consortium Study 99-08. Clin Cancer Res 2006; 12: 4899-4907.
73. Garton, A. Combined treatment with an EGFR kinase inhibitor and an inhibitor of c-kit. WO2009073139 (2009).
74. Garton AJ, Crew AP, Franklin M, Cooke AR, Wynne GM, Castaldo L, et al. OSI-930: A novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res 2006; 66: 1015-1024.
75. Reardon D, Egorin M, Quinn J, Rich Sr J, Gururangan I, Vredenburgh J, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005; 23: 9359-9368.
76. O'Connor OA. Pralatrexate: An emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 2006; 18: 591-597.
77. Izbicka E, Diaz A, Streeper R, Wick M, Campos D, Steffen R, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 2009; 64: 993-999.
78. Wang E, O'Connor O, She Y, Zelenetz A, Sirotnak F, Moore M. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003; 44: 1027-1035.
79. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 1998; 42: 313-318.
80. Krug LM, Heelan RT, Kris MG, Venkatraman E, Sirotnak FM. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol 2007; 2: 317-320.
81. Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010; 16: 3648-3658.
82. Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, et al. 10-Propargyl-10-deazaaminopterin: An antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 2003; 9: 2072-2078.
83. Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, et al. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin Cancer Res 2007; 13: 2692-2698.
84. Steffen, R. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer. US20090048262 (2009).
85. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 2009; 6: 395-404.
86. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 708-715.
87. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003; 21: 2299-2304.
88. Chang SM, Lamborn KR, Malec M, Larson D, Wara W, Sneed P, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2004; 60: 353-357.
89. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.
90. Desjardins A, Reardon DA, Herndon JE, 2nd, Marcello J, Quinn JA, Rich JN, et al. Bevacizumab plus irinotecan in recurrent WHO grade III malignant gliomas. Clin Cancer Res 2008; 14: 7068-7073.
91. Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
92. Kanthou C, Tozer GM. Tumour targeting by microtubuledepolymerizing vascular disrupting agents. Expert Opin Ther Targets 2007; 11: 1443-1457.
93. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413-6422.
94. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829-1834.
95. Eikesdal HP, Schem BC, Mella O, Dahl O. The new tubulininhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. Int J Radiat Oncol Biol Phys 2000; 46: 645-652.
96. Eikesdal HP, Bjerkvig R, Raleigh JA, Mella O, Dahl O. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiother Oncol 2001; 61: 313-320.
97. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408-3416.
98. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 2003; 21: 2815-2822.
99. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21: 4428-4438.
100. Ng Q-S, Goh V, Carnell D, Meer K, Padhani A, Saunders M, et al. Tumor antivascular effects of radiotherapy combined with combretastatin A4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 67: 1375-1380.
101. Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010; 102: 1355-1360.
102. Chaplin, D., Silm, B. Methods and compositions for enhancing the efficacy of RTK inhibitors. WO2009103076 (2009).